MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) announced that the U.S. Drug Enforcement Administration has conducted a scientific review and determined that investigational cannabinoid Supera-CBD is ...

Cannabis (Cannabis sativa) is well known for the euphoric “high” it gives users, caused by a chemical called tetrahydrocannabinol (THC). Another component, CBD, is responsible for feelings of ...

MyMD’s second therapeutic candidate is Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD) analog that is 8000 times more potent a CB2 agonist (activator) than plant-based CBD.

Supera-CBD is a unique synthetic analog of CBD whose structure has been modified to be CB2-receptor selective. Studies to investigate Supera-CBD’s binding and affinity to CB1 and CB2 receptors show ...